Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Generation Bio

Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid therapeutics. Moderna will make an upfront payment of $40 million in cash, in addition to a $36 million equity investment “at a premium over recent share prices.

Generation Bio, Moderna announce collaboration

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio's ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program Moderna will fund all research and development activities under the collaboration Generation Bio will receive a $40 million upfront cash payment, a pre-payment of research funding, plus a $36 million equity investment from Moderna, with the potential for additional milestones, fees, and royalties CAMBRIDGE, MA / ACCESSWIRE / March 23, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Moderna's share price has soared over 896% in the last 5 years, compared to just 60% for the S&P 500. That success is built on the company's Covid-19 vaccine.

Moderna Is Great Value For Money Right Now

Moderna CEO Stéphane Bancel tried to defend the company's plan to increase the price of its COVID-19 vaccine during a congressional hearing that raised longstanding questions about how drugs should be priced in the U.S.

Moderna CEO defends price increase for COVID vaccine to Congress

Bernie Sanders pressed Stephane Bancel during the Senate hearing to make a commitment that Moderna will not increase the vaccine's list price to $130.

Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling

"On top of all this, we're expecting a 90% reduction in demand," Bancel said. "As you can see, we're losing economies of scale.

Moderna CEO defends $130 COVID vax price after Bernie Sanders jab

Moderna, Inc. stock's downward spiral from its December highs accelerated, with a staggering 40% collapse toward its March lows. Beyond its COVID vaccine triumph, Moderna must prove its mettle in sustaining operating profitability and growth.

Moderna: Now's Your Chance (Rating Upgrade)

The company is preparing for commercial distribution of the shots as the U.S. winds down its pandemic-emergency purchases.

Moderna to Price Its Covid-19 Vaccine at $130 a Dose

Sen. Bernie Sanders is expected to focus on the company's plans to charge insurers $130 per dose for its Covid-19 vaccine.

Moderna CEO to Face Senate Committee About Covid Vaccine Pricing

Pfizer

Loading up on quality stocks while valuations are low is a good idea. Pfizer's pipeline will be getting a bolt-on expansion with its Seagen acquisition.

2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market

GlaxoSmithKline

The vaccine's revenue would help Pfizer make up for looming patent cliffs. GSK's annual financials were the healthiest of the three companies.

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

Lumen Technologies

The recent bank failures have introduced a new risk into the stock market. Lumen stock is being removed from the S&P 500 after a long decline and more problems in its fourth-quarter earnings report.

Is It Time to Buy the S&P 500's 2 Worst-Performing February Stocks?

Moderna recently announced an expansion plan, which includes hiring new employees and opening new offices. This is a sign of the company's confidence in its own future.

This High-Growth Company Is Expanding. Time to Buy the Stock?

Is Moderna stock a sell after massively missing 2023 sales guidance expectations on a mixed quarterly report? Is MRNA stock a sell?

Is Moderna Stock A Sell After Waning Covid Shots Crush Its 2023 Outlook?

Vertex Pharmaceuticals

With three pipeline candidates in phase 3 clinical trials, Moderna is set to enter a new phase of growth. CRISPR Therapeutics may soon reach a big milestone -- the launch of its first approved product.

2 Top Biotech Stocks to Buy for the Long Haul

Novavax

During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.

Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting

JD.com

Sirius XM Holdings Inc

JD.com is based in China, which is why many investors stay away from it. Even in a tough advertising market, SiriusXM managed to grow.

Is It Time to Buy the Nasdaq's 3 Worst-Performing February Stocks?

Etsy

Home Depot

Teladoc

Target

Today's difficult market has left many quality companies trading at bargain prices. Now is time to find these deals -- and invest for the long term.

A Bull Market Is Coming: 5 Top Stocks to Buy Now

An analyst got notably more bullish on the well-known biotech, upgrading his recommendation on its shares. The market responded with a share bump-up.

Why Moderna Stock Zoomed 7% Higher Today

Maravai LifeSciences Holdings

Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.

2 Top Biotech Stocks to Buy In March and Hold Forever

Exact Sciences

Moderna is helping move the vaccine industry forward with its mRNA approach. Exact Sciences' products help patients and physicians better fight against cancer.

A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold

Moderna Inc. MRNA, +2.59% said Friday it is expanding in the U.S., opening new offices in South San Francisco, Calif., and Seattle, and hiring 2,000 workers worldwide by the end of the year.

Moderna plans to hire 2,000 workers, open new offices in West Coast

Biotech giant Moderna will open tech office in Seattle, plans to hire up to 220 workers

Moderna Inc said on Friday it was planning to hire about 2,000 employees globally by 2023-end and set up new offices on the U.S. West Coast, as it aims to scale up development of new products amid declining COVID vaccine sales.

News for Moderna Stock (MRNA)